| Report ID | 278169 |
| Drug Identification Number | 02324962 |
| Brand name | SANDOZ ATORVASTATIN |
| Common or Proper name | ATORVASTATIN |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | ATORVASTATIN |
| Strength(s) | 40MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 500FCT |
| ATC code | C10AA |
| ATC description | LIPID MODIFYING AGENTS, PLAIN |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2026-02-16 |
| Estimated end date | 2026-02-20 |
| Actual end date | 2026-02-23 |
| Shortage status | Resolved |
| Updated date | 2026-02-25 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4600 RUE ARMAND-FRAPPIER SAINT-HUBERT, QUEBEC CANADA J3Z 1G5 |
| Company contact information | 1 800-361-3062 |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2026-02-25 | French | Compare |
| v5 | 2026-02-25 | English | Compare |
| v4 | 2026-02-23 | French | Compare |
| v3 | 2026-02-23 | English | Compare |
| v2 | 2026-02-16 | French | Compare |
| v1 | 2026-02-16 | English | Compare |
Showing 1 to 6 of 6